Breaking News Bar

Business News and Information

Why PhaseBio's stock price more than doubled today

The Malvern biopharmaceutical company reported positive results for an early-stage study of its experimental reversal agent for a blood thinning medicine.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear